HLAG Antikörper (FITC)

Produktnummer ABIN94364

Produktdetails anti-HLAG Antikörper (FITC)

Target: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser HLAG Antikörper ist konjugiert mit FITC

Applikation: Flow Cytometry (FACS)

Spezifität: The antibody 87G recognizes both membrane-bound and soluble forms of HLA-G (HLA-G1 and HLA-G5). HLA-G belongs to the MHC Class I molecules (MHC Class Ib, nonclassical) and it is expressed on the surface of trophoblast cells.

Keine Kreuzreaktivität: Maus, Ratte

Kreuzreaktivität (Details): Human

Aufreinigung: Purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Immunogen: HLA-B27 transgenic mice were imunized with H-2 identical murine cells transfected with and expressing genes encoding HLA-G and human beta2-microglobulin.

Klon: 87G

Isotyp: IgG2a

Anwendungsinformationen

Applikationshinweise: Flow cytometry: Extracellular and intracellular staining, recommended dilution: 2 μg/mL, positive control: JEG-3 human choriocarcinoma epithelial cell line.

Kommentare:

The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Do not freeze.
Avoid prolonged exposure to light.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

Referenzen für anti-HLAG Antikörper (FITC) (ABIN94364)

LeMaoult, Caumartin, Daouya, Favier, Le Rond, Gonzalez, Carosella: "Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells." in: Blood, Vol. 109, Issue 5, pp. 2040-8, (2007) (PubMed).

Shobu, Sageshima, Tokui, Omura, Saito, Nagatsuka, Nakanishi, Hayashi, Hatake, Ishitani: "The surface expression of HLA-F on decidual trophoblasts increases from mid to term gestation." in: Journal of reproductive immunology, Vol. 72, Issue 1-2, pp. 18-32, (2006) (PubMed).

Rouas-Freiss, Moreau, Ferrone, Carosella: "HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?" in: Cancer research, Vol. 65, Issue 22, pp. 10139-44, (2005) (PubMed).

Hackmon, Hallak, Krup, Weitzman, Sheiner, Kaplan, Weinstein: "HLA-G antigen and parturition: maternal serum, fetal serum and amniotic fluid levels during pregnancy." in: Fetal diagnosis and therapy, Vol. 19, Issue 5, pp. 404-9, (2004) (PubMed).

Ishitani, Sageshima, Lee, Dorofeeva, Hatake, Marquardt, Geraghty: "Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 171, Issue 3, pp. 1376-84, (2003) (PubMed).

Menier, Saez, Horejsi, Martinozzi, Krawice-Radanne, Bruel, Le Danff, Reboul, Hilgert, Rabreau, Larrad, Pla, Carosella, Rouas-Freiss: "Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules." in: Human immunology, Vol. 64, Issue 3, pp. 315-26, (2003) (PubMed).

Poláková, Bandzuchová, Hofmeister, Weiss, Hutter, Russ: "Binding analysis of HLA-G specific antibodies to hematopoietic cells isolated from leukemia patients." in: Neoplasma, Vol. 50, Issue 5, pp. 331-8, (2003) (PubMed).

Poláková, Krcová, Kuba, Russ: "Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients." in: Leukemia research, Vol. 27, Issue 7, pp. 643-8, (2003) (PubMed).

Sageshima, Ishitani, Omura, Akasaki, Umekage, Katabuchi, Okamura, Hatake: "Necrotic feature of the trophoblasts lacking HLA-G expression in normal and pre-eclamptic placentas." in: American journal of reproductive immunology (New York, N.Y. : 1989), Vol. 49, Issue 3, pp. 174-82, (2003) (PubMed).

Wiendl, Mitsdoerffer, Hofmeister, Wischhusen, Weiss, Dichgans, Lochmuller, Hohlfeld, Melms, Weller: "The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy." in: Brain : a journal of neurology, Vol. 126, Issue Pt 1, pp. 176-85, (2002) (PubMed).

Riteau, Menier, Khalil-Daher, Martinozzi, Pla, Dausset, Carosella, Rouas-Freiss: "HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition." in: International immunology, Vol. 13, Issue 2, pp. 193-201, (2001) (PubMed).

Details zu HLAG

Target: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Andere Bezeichnung: HLA-G (HLAG Produkte)

Synonyme: MHC-G antikoerper, B-F antikoerper, B-F-S04 antikoerper, B-F-S05 antikoerper, B-F-S06 antikoerper, B-F-S07 antikoerper, B-FI antikoerper, B-FIV antikoerper, BF2 antikoerper, BFa2 antikoerper, BFw-03 antikoerper, BFw-05 antikoerper, BFz-01 antikoerper, major histocompatibility complex, class I, G antikoerper, MHC BF1 class I antikoerper, HLA-G antikoerper, BF1 antikoerper

Hintergrund: Major histocompatibility complex, class I, G,Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.

Gen-ID: 3135

UniProt: P17693

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints, Human Leukocyte Antigen (HLA) in Adaptive Immune Response